Journal
CLINICAL INFECTIOUS DISEASES
Volume 51, Issue -, Pages S42-S47Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/653048
Keywords
-
Categories
Funding
- Cerexa/Forest
- Ortho-McNeil
- Pfizer
- Boehringer Ingelheim
- Tibotec
- Wyeth
- Glaxo SmithLkine
- Protez/Novartis
- Merck
- Nabriva
- US Food and Drug Administration
- Infectious Diseases Society of America
- American College of Chest Physicians
- American Thoracic Society
- Society of Critical Care Medicine
- Pharmaceutical Research and Manufacturers of America
- AstraZeneca Pharmaceuticals
- Forest Pharmaceuticals
Ask authors/readers for more resources
Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future clinical trials. Despite some differences (mostly related to likely pathogens), there is a general agreement about the recommended approach to management. All of the reviewed guidelines invariably recommend early, appropriate antimicrobial therapy and avoidance of excessive antimicrobials by deescalation of therapy on the basis of microbiological culture results and the clinical response of the patient. Developers of future clinical trials will need to be mindful of these recommendations to maintain best practice care for each investigator.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available